Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SAGE

SAGE - Sage Therapeutics Inc Stock Price, Fair Value and News

11.99USD+0.49 (+4.26%)Market Closed

Market Summary

SAGE
USD11.99+0.49
Market Closed
4.26%

SAGE Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

SAGE Stock Price

View Fullscreen

SAGE RSI Chart

SAGE Valuation

Market Cap

721.6M

Price/Earnings (Trailing)

-1.43

Price/Sales (Trailing)

7.92

Price/Free Cashflow

-1.7

SAGE Price/Sales (Trailing)

SAGE Profitability

Operating Margin

98.37%

Return on Equity

-71.29%

Return on Assets

-65.55%

Free Cashflow Yield

-58.91%

SAGE Fundamentals

SAGE Revenue

Revenue (TTM)

91.1M

Rev. Growth (Yr)

139.89%

Rev. Growth (Qtr)

-89.87%

SAGE Earnings

Earnings (TTM)

-503.1M

Earnings Growth (Yr)

26.12%

Earnings Growth (Qtr)

-231.69%

Breaking Down SAGE Revenue

Last 7 days

13.3%

Last 30 days

2.4%

Last 90 days

-40.0%

Trailing 12 Months

-78.6%

How does SAGE drawdown profile look like?

SAGE Financial Health

Current Ratio

12.22

SAGE Investor Care

Shares Dilution (1Y)

0.70%

Diluted EPS (TTM)

-8.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202491.1M000
20239.4M10.4M11.3M86.5M
20226.3M6.2M6.5M7.7M
2021837.2M560.3M283.3M6.3M
20207.9M8.9M561.6M1.1B
2019062.5M34.7M6.9M
201800090.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Sage Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 13, 2024
iguchi kimi
acquired
-
-
11,250
cfo & treasurer
Feb 13, 2024
cook anne marie
acquired
-
-
11,250
svp, gc & secretary
Feb 13, 2024
gault laura
acquired
-
-
11,250
chief medical officer
Feb 13, 2024
benecchi christopher
acquired
-
-
13,500
chief business officer
Jan 02, 2024
iguchi kimi
acquired
2,233
1.36
1,642
cfo & treasurer
Nov 28, 2023
iguchi kimi
sold (taxes)
-18,171
19.27
-943
cfo & treasurer
Nov 28, 2023
jonas jeffrey m
sold (taxes)
-75,827
19.27
-3,935
-
Nov 28, 2023
iguchi kimi
acquired
-
-
3,500
cfo & treasurer
Nov 28, 2023
cook anne marie
sold (taxes)
-22,623
19.27
-1,174
svp, gc & secretary
Nov 28, 2023
cook anne marie
acquired
-
-
4,000
svp, gc & secretary

1–10 of 50

Which funds bought or sold SAGE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-68,000
420,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
sold off
-100
-456,000
-
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
-125,404
802,072
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.56
66,522
216,522
0.03%
May 20, 2024
Virtu Financial LLC
new
-
187,000
187,000
0.01%
May 16, 2024
COMERICA BANK
reduced
-2.98
-1,172
6,109
-%
May 16, 2024
JANE STREET GROUP, LLC
added
196
2,337,080
3,832,050
-%
May 16, 2024
FSA Wealth Management LLC
unchanged
-
-344
656
-%
May 16, 2024
Ancora Advisors LLC
unchanged
-
-220
1,405
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.92
-218,420
1,010,160
-%

1–10 of 42

Are Funds Buying or Selling SAGE?

Are funds buying SAGE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SAGE
No. of Funds

Unveiling Sage Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
fmr llc
-
0
SC 13G/A
Jun 10, 2024
vanguard group inc
10.47%
6,302,547
SC 13G/A
Jun 06, 2024
wellington management group llp
0.07%
39,757
SC 13G/A
Feb 14, 2024
rtw investments, lp
8.7%
5,197,019
SC 13G
Feb 13, 2024
bb biotech ag
5.8%
3,505,000
SC 13G/A
Feb 13, 2024
vanguard group inc
8.86%
5,319,360
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
10.10%
6,061,996
SC 13G/A
Jan 26, 2024
blackrock inc.
7.8%
4,663,900
SC 13G/A
Jan 24, 2024
state street corp
6.53%
3,918,222
SC 13G

Recent SEC filings of Sage Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
8-K
Current Report
Jun 11, 2024
8-K
Current Report
Jun 10, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Sage Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Sage Therapeutics Inc News

Latest updates
MarketBeat4 hours ago
MarketBeat13 Jun 202406:08 pm
Defense World13 Jun 202405:15 pm
Yahoo Canada Shine On12 Jun 202407:06 pm
Seeking Alpha11 Jun 202412:23 pm

Sage Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue-89.9%7,902,00077,971,5002,716,0002,474,0003,294,0002,864,5001,739,0001,501,0001,582,0001,642,0001,440,0001,643,0001,504,5001,366,0001,227,5001,089,0002,286,0001,960,0003,570,00025,177,50046,785,000
Cost Of Revenue---905,000205,000230,000143,000184,000200,000286,00087,000131,000148,000187,000136,000149,000110,000170,000-137,00044,000-
Operating Expenses4.6%125,577,000120,045,000214,565,000172,931,000158,764,000156,767,000143,219,000129,908,000124,781,000127,129,000132,334,000109,664,00098,090,000135,211,000108,797,000140,056,000133,910,000176,598,000190,747,000177,330,000164,500,000
  S&GA Expenses-4.6%52,574,00055,109,00078,142,00075,565,00065,708,00067,329,00061,482,00052,411,00046,477,00051,599,00048,706,00043,346,00039,847,00053,498,50035,099,00038,224,00070,130,00085,129,00088,502,00088,227,00075,695,000
  R&D Expenses11.5%71,734,00064,329,500101,919,00097,161,00092,826,00089,295,00081,553,00077,297,00078,018,00075,443,00083,497,00066,170,00058,056,00081,706,00074,078,00073,320,00063,610,00091,250,000102,108,00089,059,00088,805,000
EBITDA Margin---------74.06-73.13-71.93--0.540.54-1.21-76.26-26.97-16.38-6.44-5.02-
EBT Margin---------74.27-73.42-72.59--0.540.54-1.21-76.39-27.02-16.41-6.46-5.04-
Net Income-231.7%-108,483,000-32,706,000-201,630,000-160,325,000-146,828,000-147,146,000-137,323,000-126,260,000-122,055,000-124,712,000-130,171,000-107,245,000-95,764,000974,895,000-105,735,000-136,347,000-126,740,000-168,653,000-179,958,000-168,221,000-158,388,000
Net Income Margin11.8%-5.53-6.26-57.80-57.04-59.32-69.31-78.95-81.62-76.77-72.592.271.19---------
Free Cashflow68.3%-37,832,000-119,407,000-136,194,000-131,630,000-153,907,000-127,214,000-119,229,000-106,561,000-107,969,000-97,501,000-68,826,000-102,769,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-13.0%7688829501,0821,2211,3561,4861,6011,7061,8251,9272,0152,0812,1597398279451,0841,2041,3161,423
  Current Assets-13.1%7558699331,0641,2031,3371,4651,5791,6821,8011,9021,9892,0522,1226997858981,0351,1531,2641,372
    Cash Equivalents143.2%17371.001491212071632002071792944225148991,661184258199127259166342
  Net PPE-17.5%2.002.002.002.003.003.003.003.003.003.003.003.004.007.007.008.009.009.009.008.007.00
Liabilities-25.3%62.0083.0013398.0088.0010410697.0087.0096.0092.0086.0077.0087.0081.0087.0096.00139123113103
  Current Liabilities-25.3%62.0083.0013397.0085.0099.0010089.0078.0085.0079.0072.0062.0067.0060.0064.0070.0011291.0079.0068.00
Shareholder's Equity-11.7%7068008179841,1331,2531,3801,5041,6191,7291,8361,9302,0032,0726587408499451,0811,2031,320
  Retained Earnings-4.2%-2,678-2,569-2,536-2,335-2,175-2,028-1,881-1,743-1,617-1,495-1,370-1,240-1,100-1,037-2,012-1,900-1,770-1,643-1,474-1,300-1,126
  Additional Paid-In Capital0.4%3,3853,3703,3583,3263,3143,2913,2763,2623,2483,2273,2073,1713,1373,1102,6692,6452,6212,5872,5552,4972,447
Shares Outstanding0.2%60.0060.0060.0060.0060.0060.0059.0059.0059.0059.0059.0058.00---------
Float----2,471---1,686---2,934---2,121---9,274-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations68.3%-37,832-119,519-135,866-131,518-153,682-126,932-118,865-106,439-107,800-97,501-68,826-102,769-109,0861,010,971-91,016-118,984-136,691-116,726-128,702-133,344-149,934
  Share Based Compensation5.8%13,69812,94528,69111,69320,03815,24413,16914,63618,55320,64834,34227,66321,97620,74420,10824,03231,11030,67943,66934,76744,116
Cashflow From Investing231.5%139,43642,061160,39245,593194,86789,777110,952134,262-9,558-30,261-24,983-288,388-658,81645,51913,513177,382206,270-17,916207,779-58,109-274,910
Cashflow From Financing694.3%1,557-2622,7708472,67229.001,22913.001,799-1701,8166,0655,623419,6713,5453863,1602,16613,91915,343576,196
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SAGE Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 7,902$ 3,294
Operating costs and expenses:  
Cost of revenues1,269230
Research and development71,73492,826
Selling, general and administrative52,57465,708
Total operating costs and expenses125,577158,764
Loss from operations(117,675)(155,470)
Interest income, net9,2048,830
Other expense, net(12)(188)
Net loss$ (108,483)$ (146,828)
Net loss per share - basic$ (1.8)$ (2.46)
Net loss per share - diluted$ (1.8)$ (2.46)
Weighted average number of common shares outstanding— basic60,136,19859,674,127
Weighted average number of common shares outstanding— diluted60,136,19859,674,127
Comprehensive loss:  
Net loss$ (108,483)$ (146,828)
Other comprehensive items:  
Unrealized gain on marketable securities275,118
Total comprehensive loss(108,456)(141,710)
Product Revenue [Member]  
Total revenue1,690$ 3,294
Collaboration Revenue - Related Party [Member]  
Total revenue$ 6,212 

SAGE Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 172,653$ 70,992
Marketable securities544,360682,192
Prepaid expenses and other current assets26,58831,825
Collaboration receivable - related party10,50983,009
Restricted cash$ 1,332$ 1,332
Accounts Receivable, after Allowance for Credit Loss, Current, Related Party, Type [Extensible Enumeration]Related Party [Member]Related Party [Member]
Total current assets$ 755,442$ 869,350
Property and equipment, net1,5851,921
Restricted cash1,5000
Right-of-use operating asset2,8574,458
Other long-term assets6,2166,548
Total assets767,600882,277
Current liabilities:  
Accounts payable6,47910,318
Accrued expenses52,01467,264
Operating lease liability, current portion3,3065,165
Total current liabilities61,79982,747
Total liabilities61,79982,747
Commitments and contingencies (Note 6)
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2014 and December 31, 2023; 60,185,064 and 60,046,676 shares issued at March 31, 2024 and December 31, 2023; 60,182,031 and 60,043,643 shares outstanding at March 31,2024 and December 31, 202366
Treasury stock, at cost, 3,033 shares at March 31, 2024 and December 31, 2023(400)(400)
Additional paid-in capital3,385,1243,370,397
Accumulated deficit(2,678,142)(2,569,659)
Accumulated other comprehensive loss(787)(814)
Total stockholders’ equity705,801799,530
Total liabilities and stockholders’ equity$ 767,600$ 882,277
SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEsagerx.com
 INDUSTRYBiotechnology
 EMPLOYEES689

Sage Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Sage Therapeutics Inc? What does SAGE stand for in stocks?

SAGE is the stock ticker symbol of Sage Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sage Therapeutics Inc (SAGE)?

As of Fri Jun 14 2024, market cap of Sage Therapeutics Inc is 721.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers. The fair value of Sage Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sage Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SAGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sage Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SAGE is over valued or under valued. Whether Sage Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sage Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAGE.

What is Sage Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, SAGE's PE ratio (Price to Earnings) is -1.43 and Price to Sales (PS) ratio is 7.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAGE PE ratio will change depending on the future growth rate expectations of investors.